ETFIQData as of Nov 19, 2026. · etfiq.com/funds/idna

IDNA Fact Sheet: iShares Genomics Immunology and Healthcare ETF

Share
$37.00
close, Nov 20, 2026

Over the year to Nov 19, 2026, IDNA returned +47.2% in total and charged 0.47% a year.

1-year total return
+44.7%
to Nov 20, 2026
Expense ratio
0.47%
a year
Net assets
$320m
on Nov 19, 2026
Net flow, last 5 trading days
+$4.1m
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

IDNA $14,724 +47.2% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−13.3%
3 months−7.7%
Year to date+41.9%
1 year+44.7%
3 years+92.5%
5 years−18.6%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
MODERNA13.00%
GENMAB6.45%
TWIST BIOSCIENCE4.99%
REGENERON PHARMACEUTICALS4.50%
BAYER AG4.45%
TAKEDA PHARMACEUTICAL4.37%
EXELIXIS INC3.86%
VERTEX PHARMACEUTICALS3.61%
ROCHE PS PAR AG3.56%
INCYTE CORP3.50%

IDNA top ten by weight, 52.3% of the fund, of its 51 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 51 stocks in genomics and gene editing, 28% of its weight in S&P 500 companies · First traded Jun 13, 2019 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, IDNA Fact Sheet: iShares Genomics Immunology and Healthcare ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/idna/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/idna.